Aripiprazole Sandoz

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

aripiprazole

Available from:

Sandoz GmbH

ATC code:

N05AX12

INN (International Name):

aripiprazole

Therapeutic group:

Psikolettiċi

Therapeutic area:

Schizophrenia; Bipolar Disorder

Therapeutic indications:

Aripiprazole Sandoz huwa indikat għall-kura ta 'l-iskiżofrenja fl-adulti u fl-adolexxenti ta' 15-il sena jew aktar. Aripiprazole Sandoz huwa indikat għat-trattament ta 'episodji manijaċi serji f'Disturb Bipolari I u għall-prevenzjoni ta' episodju manijaku ġdid f'adulti li esperjenzaw episodji predominantament manijaċi u li l-episodji manijaċi rrispondew għat-trattament b'aripiprazole. Aripiprazole Sandoz huwa indikat għall-kura sa 12-il ġimgħa ta 'episodji manijaċi serji f'Disturb Bipolari I fl-adolexxenti ta' minn 13-il sena u anzjani.

Product summary:

Revision: 9

Authorization status:

Awtorizzat

Authorization date:

2015-08-20

Patient Information leaflet

                                55
B. FULJETT TA’ TAGĦRIF
56
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
ARIPIPRAZOLE SANDOZ 5 MG PILLOLI
ARIPIPRAZOLE SANDOZ 10 MG PILLOLI
ARIPIPRAZOLE SANDOZ 15 MG PILLOLI
ARIPIPRAZOLE SANDOZ 20 MG PILLOLI
ARIPIPRAZOLE SANDOZ 30 MG PILLOLI
aripiprazole
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
•
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
•
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
•
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
•
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Aripiprazole Sandoz u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Aripiprazole Sandoz
3.
Kif għandek tieħu Aripiprazole Sandoz
4.
Effetti sekondarji possibbli
5.
Kif taħżen Aripiprazole Sandoz
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU ARIPIPRAZOLE SANDOZ U GĦALXIEX JINTUŻA
Aripiprazole Sandoz fih is-sustanza attiva aripiprazole u jappartjeni
għal grupp ta’ mediċini msejħa
antipsikotiċi. Jintuża biex jiġu kkurati adulti u adolexxenti li
għandhom 15-il sena jew aktar li jbatu
minn marda kkaratterizzata minn sintomi bħalma huma smigħ, viżta
jew ħass ta’ affarijiet li mhumiex
hemm, suspetti, ħsieb ħażin, diskors li ma jiftehimx u mġiba
mħawwda u mingħajr emozzjoni. Nies li
jbatu b’din il-kundizzjoni jistgħu wkoll iħossuhom imdejqin,
ħatja, u b’tensjoni.
Aripiprazole Sandoz jintużaw biex jikkuraw adulti u adolexxenti li
għandhom 13-il sena jew aktar li
jbatu minn kundizzjoni b’sintomi bħalma huma li wieħed iħossu
ferħan iżżejjed, ikollu ammonti
eċċessivi ta’ enerġija, jeħtieġ ferm inqas irqad min-normal,
jitkellem malajr 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Aripiprazole Sandoz 5 mg pilloli
Aripiprazole Sandoz 10 mg pilloli
Aripiprazole Sandoz 15 mg pilloli
Aripiprazole Sandoz 20 mg pilloli
Aripiprazole Sandoz 30 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Aripiprazole Sandoz 5 mg pilloli
Kull pillola fiha 5 mg ta’ aripiprazole.
Eċċipjent(i) b’effett magħruf
67.47 mg lactose (bħala monohydrate) kull pillola.
Aripiprazole Sandoz 10 mg pilloli
Kull pillola fiha 10 mg ta’ aripiprazole.
Eċċipjent(i) b’effett magħruf
62.67 mg lactose (bħala monohydrate) kull pillola.
Aripiprazole Sandoz 15 mg pillola
Kull pillola fiha 15 mg ta’ aripiprazole.
Eċċipjent(i) b’effett magħruf
92.86 mg lactose (bħala monohydrate) kull pillola.
Aripiprazole Sandoz 20 mg pillola
Kull pillola fiha 20 mg ta’ aripiprazole.
Eċċipjent(i) b’effett magħruf
125.72 mg lactose (bħala monohydrate) kull pillola.
Aripiprazole Sandoz 30 mg pillola
Kull pillola fiha 30 mg ta’ aripiprazole.
Eċċipjent(i) b’effett magħruf
186.68 mg lactose (bħala monohydrate) kull pillola.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola
3
Aripiprazole Sandoz 5 mg pilloli
Pillola tonda, bit-tikek, ta’ lewn blu, b’dijametru ta’ bejn
wieħed u ieħor 6.0 mm, imnaqqxa b’“SZ”
fuq naħa waħda u “444” fuq in-naħa l-oħra.
Aripiprazole Sandoz 10 mg pilloli
Pillola tonda, bit-tikek, ta’ lewn roża, b’dijametru ta’ bejn
wieħed u ieħor 6.0 mm, imnaqqxa b’“SZ”
fuq naħa waħda u “446” fuq in-naħa l-oħra.
Aripiprazole Sandoz 15 mg pilloli
Pillola tonda, bit-tikek, ta’ lewn isfar, b’dijametru ta’ bejn
wieħed u ieħor 7.0 mm, imnaqqxa b’“SZ”
fuq naħa waħda u “447” fuq in-naħa l-oħra.
Aripiprazole Sandoz 20 mg pilloli
Pillola tonda, bit-tikek, ta’ lewn abjad, b’dijametru ta’ bejn
wieħed u ieħor 7.8 mm, imnaqqxa b’“SZ”
fuq naħa waħda u “448” fuq in-naħa l-oħra.
_ _
_ _
Aripiprazole Sandoz 30 mg p
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-02-2024
Public Assessment Report Public Assessment Report Bulgarian 25-09-2015
Patient Information leaflet Patient Information leaflet Spanish 27-02-2024
Public Assessment Report Public Assessment Report Spanish 25-09-2015
Patient Information leaflet Patient Information leaflet Czech 27-02-2024
Public Assessment Report Public Assessment Report Czech 25-09-2015
Patient Information leaflet Patient Information leaflet Danish 27-02-2024
Public Assessment Report Public Assessment Report Danish 25-09-2015
Patient Information leaflet Patient Information leaflet German 27-02-2024
Public Assessment Report Public Assessment Report German 25-09-2015
Patient Information leaflet Patient Information leaflet Estonian 27-02-2024
Public Assessment Report Public Assessment Report Estonian 25-09-2015
Patient Information leaflet Patient Information leaflet Greek 27-02-2024
Public Assessment Report Public Assessment Report Greek 25-09-2015
Patient Information leaflet Patient Information leaflet English 27-02-2024
Public Assessment Report Public Assessment Report English 25-09-2015
Patient Information leaflet Patient Information leaflet French 27-02-2024
Public Assessment Report Public Assessment Report French 25-09-2015
Patient Information leaflet Patient Information leaflet Italian 27-02-2024
Public Assessment Report Public Assessment Report Italian 25-09-2015
Patient Information leaflet Patient Information leaflet Latvian 27-02-2024
Public Assessment Report Public Assessment Report Latvian 25-09-2015
Patient Information leaflet Patient Information leaflet Lithuanian 27-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-02-2024
Public Assessment Report Public Assessment Report Lithuanian 25-09-2015
Patient Information leaflet Patient Information leaflet Hungarian 27-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 27-02-2024
Public Assessment Report Public Assessment Report Hungarian 25-09-2015
Patient Information leaflet Patient Information leaflet Dutch 27-02-2024
Public Assessment Report Public Assessment Report Dutch 25-09-2015
Patient Information leaflet Patient Information leaflet Polish 27-02-2024
Public Assessment Report Public Assessment Report Polish 25-09-2015
Patient Information leaflet Patient Information leaflet Portuguese 27-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 27-02-2024
Public Assessment Report Public Assessment Report Portuguese 25-09-2015
Patient Information leaflet Patient Information leaflet Romanian 27-02-2024
Public Assessment Report Public Assessment Report Romanian 25-09-2015
Patient Information leaflet Patient Information leaflet Slovak 27-02-2024
Public Assessment Report Public Assessment Report Slovak 25-09-2015
Patient Information leaflet Patient Information leaflet Slovenian 27-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 27-02-2024
Public Assessment Report Public Assessment Report Slovenian 25-09-2015
Patient Information leaflet Patient Information leaflet Finnish 27-02-2024
Public Assessment Report Public Assessment Report Finnish 25-09-2015
Patient Information leaflet Patient Information leaflet Swedish 27-02-2024
Public Assessment Report Public Assessment Report Swedish 25-09-2015
Patient Information leaflet Patient Information leaflet Norwegian 27-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 27-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 27-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 27-02-2024
Patient Information leaflet Patient Information leaflet Croatian 27-02-2024
Public Assessment Report Public Assessment Report Croatian 25-09-2015

Search alerts related to this product